Spots Global Cancer Trial Database for Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

Official Title: Indentifying Epigenetic Biomarkers From Peripheral Blood of Advanced Osteosarcoma Patients, Who Recieve Famitinib and Camrelizumab Based on hMe-Seal Technique

Study ID: NCT03919539

Conditions

Drug Resistance to Famitinib and Camrelizumab

Biomarkers for Efficacy and Toxicity

Interventions

5hmc testing

Study Description

Brief Summary: hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma. From our previous trials, we identify geno sequencing related to beta-catenin pathways might have some relationship with osteosaroma primary or secondary drug resistance. Thus in this trial we try to further explore the drug resistance mechanism for advaced osteosarcoma second resistance to the combination therapy of Famitinib and Camrelizumab.

Detailed Description: